

5<sup>th</sup> World

# HEART AND BRAIN CONFERENCE

September 24-26, 2018 Abu Dhabi, UAE

## Omega-3 fatty acids and malignant ventricular arrhythmias in patients with implantable cardioverter defibrillator

Sabrina Zeghichi-Hamri<sup>1,2</sup>, Patricia Salen<sup>2</sup>, Michel de Lorgeril<sup>2</sup> and Pascal Defaye<sup>3</sup><sup>1</sup>University of Bejaia, Algeria<sup>2</sup>Joseph Fourier University, France<sup>3</sup>Centre Hospitalier Universitaire de Grenoble, France

**Background:** Studies that evaluated the effects of omega-3 polyunsaturated fatty acids (n-3) on cardiovascular diseases have yielded conflicting results. We aimed at examining the association between plant/marine n-3 and Malignant Ventricular Arrhythmias (MVA) among patients benefiting from the best preventive strategy including Implantable Cardioverter Defibrillator (ICD).

**Method:** Consecutive patients in whom an ICD was implanted for primary or secondary prevention of MVA were eligible. All patients had blood fatty acid analysis. The method of Kaplan-Meier was used to estimate the survival curves in each quartile of the main plant (ALA) and marine (EPA and DHA) n-3.

**Results:** Among the 238 enrolled patients, 100 had a relevant endpoint recorded by the ICD or died from a cardiac cause during a mean follow-up of 30±12 months. No significant difference in MVA was observed between quartiles of ALA (log-rank test p=0.88), EPA (log-rank test p=0.58) and DHA (log-rank test p=0.97). In a multivariate cox proportional hazard model including age, sex, ischemic heart disease, diabetes, smoking, hypertension and high cholesterol as covariates, we found no association between MVA and n-3: Hazard ratio was 1.12 (95% CI 0.62-2.02) for ALA and 1.44 (95% CI 0.81-2.58) for the sum of main marine n-3.

**Conclusion:** Plant and marine n-3 do not seem to either increase or decrease the risk of MVA in patients who are not n-3 deficient and benefit from the most effective preventive treatment. Further studies are required to test whether n-3 deficient patients would still benefit from n-3 supplements. Finally, these data raise major questions regarding interactions between dietary n-3 and certain medications.

zeghichi@yahoo.fr

**Notes:**